Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Other

Wilex Ag

Wilex Biotechnology Gmbh

Chiara Cabrele

Uwe Jacob

Kerstin Wendt

Peter Sondermann

Luis Moroder

Robert Huber

Stefan Sperl

Olaf G Wilhelm

Viktor Magdolen

Wolfram Bode

Erich Wunsch

Gerhard Ruhenstroth-Bauer

Jörg Stürzebecher

Thomas Martin

Josef Stadlwieser

Joerg Stuerzebecher

Wolf-R&uuml;diger Ulrich

Thomas B&auml;r

Ulrich Thibaut

Christian Sommerhoff

Rolf Beume

Gunter Valet

Norbert Schaschke

Andreas Bergner

Pedro Jose Barbosa Pereira

Andreas Dominik

Karl-Josef Goebel

Daniela Bundschuh

Nuria Arroyo De Prada

Erich W/u/ Nsch

G/u/ Nter Valet

Cabrele Chiara

The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc&#x3b3;RIIb or Fc&#x3b3;RIIa.

Substance binding human IgG Fc receptor IIb (Fc&#x3b3;RIIb)

The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC3,4.21.31) of the aryl guanidine type.

Selective inhibitors of the urokinase plasminogen activator

A method is described for inhibiting urokinase plasminogen activator in a human or animal patient. The method involves administering to the patient a urokinase plasminogen activator inhibiting effective amount of a compound of the formula (I): 

Highly selective inhibitors of the urokinase plasminogen activator

The present invention relates to novel selective inhibitors of the urokinase plasminogene activator (uPA, EC 3.4.21.31) of the aryl guanidine type.

The invention relates generally to a novel type of arginine mimetics which are inhibitors of factor X; to pharmaceutical compositions which comprise these mimetics; and to the use of these arginine mimetics for producing compositions for antithrombotic therapy.

[object Object]

The invention relates to novel selective inhibitors of the urokinase plasminogen activator (uPA, EC 3.4.21.31), of the arylguanidine type.

Tryptase inhibitors

The invention relates to novel inhibitors of human tryptase which are used in the pharmaceutical industry for the production of medicaments.

The invention relates to a hinge peptide of the general formula I that may e utilized for the manufacture of synthetic immunogens. The invention also comprises a process for the manufacture of this hinge peptide and a process for the manufacture of synthetic immunogens, where the hinge peptide is employed as a carrier protein.

Hinge peptide, a process for its manufacture, and its use for the

A process for determining the pH value in the interior of a cell is descrd. This is accomplished by measurement of the emission of a fluorescent substance which is absorbed by the cell through incubation in a solution. The solution contains a compound of the said fluorescent substance; the fluorescent substance is separated from this compound in the cell by an enzyme present in the cell. The fluorescent substance selected is one such that the frequency of the emission maximum is dependent on the pH value. The compound of this fluorescent substance which is selected is one which is membrane penetrating. Measurement of the fluorescence is based on the principle of measurement of the frequency at which the emission maximum occurs. A fluorescent substance suitable for this purpose is 2,3-dicyano-1,4-hydroquinone. A suitable membrane penetrating compound is 1,4-diacetoxy-2,3-dicyanobenzene or 1,4-dibutyryloxy-2,3-dicyanobenzene or 1,4-di(-tert-butyloxycarbonyl-1-alanyloxy)-2,3-dicyanobenzene.

Process for determining the pH value in the interior of a cell

A process for determining the pH value in the interior of a cell is described. This is accomplished by measurement of the emission of a fluorescent substance which is absorbed by the cell through incubation in a solution. The solution contains a compound of the said fluorescent substance; the fluorescent substance is separated from this compound in the cell by an enzyme present in the cell. The fluorescent substance selected is one such that the frequency of the emission maximum is dependent on the pH value. The compound of this fluorescent substance which is selected is one which is membrane penetrating. Measurement of the fluorescence is based on the principle of measurement of the frequency at which the emission maximum occurs. A fluorescent substance suitable for this purpose is 2,3-dicyano-1,4-hydroquinone. A suitable membrane penetrating compound is 1,4-diacetoxy-2,3-dicyanobenzene or 1,4-dibutyryloxy-2,3-dicyanobenzene or 1,4-di(-tert-butyloxycarbonyl-1-alanyloxy)-2,3-dicyanobenzene.

Compounds for determining the pH value in the interior of a cell

Growing community of inventors

Martinsried, Germany

Luis Moroder